Moderna, Inc. (MRNA)
| Market Cap | 93.94B +799.5% |
| Revenue (ttm) | 2.23B -27.6% |
| Net Income | -3.15B |
| EPS | -8.01 |
| Shares Out | 399.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,769,515 |
| Open | 225.48 |
| Previous Close | 226.30 |
| Day's Range | 217.02 - 242.29 |
| 52-Week Range | 22.28 - 242.29 |
| Beta | 1.09 |
| Analysts | Hold |
| Price Target | 123.61 (-47.47%) |
| Earnings Date | Nov 6, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $123.61, which is a decrease of -47.47% from the latest price.
News
Moderna, Google DeepMind, Biocon on AI in Science
Noubar Afeyan, Co-Founder & Chairman, Moderna and Founder & CEO, Flagship Pioneering; Lila Ibrahim, Chief AI Readiness Officer, Google DeepMind; and Kiran Mazumdar-Shaw, Founder & Executive Chairperso...
Moderna price target raised to $137 from $120 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna (MRNA) to $137 from $120 and keeps a Neutral rating on the shares. Moderna’s detailed Phase 3 intismeran…
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Merck CEO Rob Davis told CNBC that he expects the company's breakthrough cancer vaccine with Moderna to get faster to make over time. Davis acknowledged that manufacturing the vaccine is a "complex sy...
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, November 6, 2026 to re...
The Big 3: PLTR, MRNA, DELL
On the fourth anniversary of the current bull market, Tim Biggam points out the pushback against stocks as crude oil and Treasury yields stay elevated. That doesn't mean he doesn't see trading opportu...
Moderna call buyer realizes 173% same-day gains
Notable profits for the buyer who lifted the $5.00 offer for 1,010 Moderna (MRNA) Oct-26 220 calls yesterday at 09:39ET when underlying shares were trading at $206.59. Shares closed at…
Moderna Stock (MRNA) Climbs 13% to Top Its 52-Week High — Here’s Why
Moderna shares ($MRNA) climbed by 13% to around $223 on Friday afternoon, pushing the U.S. biotech and pharma company past its one-year high of $212.22. The rally came as the…
Moderna stock fires past 52-week high: what's behind Friday's rally?
Moderna MRNA shares jumped more than 9% in early trading Friday, reaching a fresh 52-week high as the biotechnology company returned to the Nasdaq-100 index. Moderna hit a 52-week high of $216.95.
Moderna price target raised to $200 from $170 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $200 from $170 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the…
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Moderna price target raised to $95 from $89 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $95 from $89 and keeps an Equal Weight rating on the shares. The firm adjusted its models for its…
Tempus AI announces multi-year collaboration with Moderna, Merck
Tempus (TEM) announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy bein...
Why Is Moderna Stock (MRNA) Falling Today, October 6?
Shares of U.S. vaccine maker Moderna ($MRNA) fell about 7% to around $190 on Tuesday afternoon. This followed an update from the World Health Organization (WHO) about the suspected plague…
Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell
Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking fu...
Nike, ON Semi, Moderna, and More Stocks That Explain Today's Market
Nike slumps after the retailer misses analysts' first-quarter earnings target and issues downbeat full-year guidance.
Why Did Moderna Stock Gain (MRNA) in After-Hours Trading on Thursday?
Moderna ($MRNA) stock inched higher by 0.16% in after-hours trading on Thursday after falling 1.89% during the regular session. The move came after Nasdaq announced that Moderna will join the…
Moderna to replace Warner Bros Discovery on Nasdaq 100
Nasdaq said on Thursday that vaccine maker Moderna will replace Warner Bros. Discovery on the Nasdaq 100 index , effective October 9.
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
Moderna's stock has been flying high lately. That has one group of analysts saying it's time to sell.
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter
Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.
Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings
Citi downgraded Moderna (MRNA) following the stock's astronomical rally in recent weeks. Boeing (BA) pens a $20 billion deal with the U.S. Navy for its next generation fighter jets.
Moderna stock falls 6% in premarket: here's why
Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell' from ‘Hold', citing concerns that its recent valuation is difficult to justify. ...
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn't enough to justify the valuation.